Abeona Therapeutics Inc vs Accenture plc — how do they compare? Abeona Therapeutics Inc trades at $7.36 (market cap $421.19M), while Accenture plc trades at $177.64 (market cap $110.04B). The key difference: Accenture plc is far larger — about 261.3× Abeona Therapeutics Inc's market cap, and Accenture plc pays a 3.63% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | ACN | |
|---|---|---|
Market Cap | $421.19M | $110.04B |
Sector | Health | Technology |
52-Week High | $7.45 | $288.54 |
52-Week Low | $4.17 | $124.41 |
Enterprise Value | $276.10M | $108.26B |
Dividend Yield | — | 3.63% |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.
The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.
Accenture (ACN) trades at $178.25, up 1.44% with strong technical and fundamental momentum. The stock shows bullish technical signals with support at $174 and resistance at $181, while recent earnings consistently beat expectations with Q1 2026 EPS of $3.80 versus $3.70 expected. Revenue growth accelerated to $69.67 billion in 2025, with solid profitability margins and attractive valuation metrics including P/E of 14.36. Recent partnerships with TEPCO and AlphaSense highlight ongoing AI-driven business transformation initiatives.
Outlook remains positive with analyst consensus price target of $189.77 offering 6.5% upside potential. Key opportunities include continued AI adoption and margin expansion, while risks involve competitive pressures and potential economic slowdown affecting consulting demand. The strong buy rating consensus (66% of analysts) supports continued investor confidence in the company's growth trajectory.
Trailing returns across standard periods
Latest headlines on both assets
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →Accenture PLC provides management and technology consulting services and solutions. The Company delivers a range of specialized capabilities and solutions to clients across all industries on a worldwide basis. Accenture operates a network of businesses provides consulting, technology, outsourcing, and alliances.
Read more on ACN →